Plasma mutational burden in PIK3CA and TP53 independently predicts early progression in patients with HR+/HER2-metastatic breast cancer (MBC) enrolled in the GEICAM/2014-12 FLIPPER trial

被引：0

作者：

Gustavo, Federico

Todo, Rojo

Meier, Lara

Martinez, Maria Teresa

Lopez, Maria Esteban

Paris, Lorena

O'Connor, Miriam

Merino, Luis De la Cruz

Santaballa, Ana

Martinez-Janez, Noelia

Anton, Fernando Moreno

Fernandez, Isaura

Keane, Maccon

Garcia-Palomo, Andres

Starus, Anna

Portela, Marta

Herranz, Jesus

Caballero, Rosalia

Jones, Frederick

Albanell, Joan

机构：

[1] Hosp Univ Fdn Jimenez Diaz, Barcelona, Spain

[2] CIBERONC ISCCIII, Barcelona, Spain

[3] GEICAM Spanish Breast Canc Grp, Barcelona, Spain

[4] Sysmex Inostics Gmbh, Hamburg, Germany

[5] Hosp Clin Univ Valencia, INCLIVA, Valencia, Spain

[6] GEICAM Spanish Breast Canc Grp, Valencia, Spain

[7] Sysmex Inostics Inc, Hamburg, Germany

[8] Ctr Oncol Galicia, La Coruna, Spain

[9] GEICAM Spanish Breast Canc Grp, La Coruna, Spain

[10] Univ Hosp Waterford Canc Trials Ireland, Waterford, Ireland

[11] Univ Seville, Hosp Univ Virgen Macarena, Dept Med, Med Oncol, Seville, Spain

[12] Hosp Univ & Politecn La Fe, Dept Med Oncol, Valencia, Spain

[13] Raman y Cajal Univ Hosp, Inst Ramon y Cajal Invest Sanitaria IRYCIS, Madrid, Spain

[14] Hosp Clin Univ San Carlos, Madrid, Spain

[15] GEICAM Spanish Breast Canc Grp, Madrid, Spain

[16] Hosp Alvaro Cunqueiro, Vigo, Spain

[17] GEICAM Spanish Breast Canc Grp, Vigo, Spain

[18] Hopsital Univ Son Espases, Palma de Mallorca, Spain

[19] GEICAM Spanish Breast Canc Grp, Palma de Mallorca, Spain

[20] Galway Univ Hosp, CIBERONC ISCIII, Galway, Ireland

[21] Complejo Asistencial Univ Leon, Leon, Spain

[22] GEICAM Spanish Breast Canc Grp, Leon, Spain

[23] Sysmex Inostics Inc, Baltimore, MD USA

[24] GEICAM Spanish Breast Canc Grp, Madrid, Spain

[25] Hosp Mar, CIBERONC ISCIII, Barcelona, Spain

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1029

引用

页数：1

共 34 条

[1] PIK3CA Mutation Assessment in HR+/HER2-Metastatic Breast Cancer: Overview for Oncology Clinical Practice
Criscitiello, Carmen
Marra, Antonio
Curigliano, Giuseppe
JOURNAL OF MOLECULAR PATHOLOGY, 2021, 2 (01): : 42 - 54
[2] A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2-Metastatic Breast Cancer
Anderson, Elizabeth J.
Mollon, Lea E.
Dean, Joni L.
Warholak, Terri L.
Aizer, Ayal
Platt, Emma A.
Tang, Derek H.
Davis, Lisa E.
INTERNATIONAL JOURNAL OF BREAST CANCER, 2020, 2020
[3] Treatment sequencing of HR+/HER2-metastatic breast cancer (mBC) patients based on PIK3CA alteration status - A retrospective analysis of a US clinicogenomics database
Turner, Stuart J.
Wang, Iris
Park, Jinhee
Kanakamedala, Hemanth
Lorenzo, Ines
CANCER RESEARCH, 2020, 80 (04)
[4] Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial
Albanell, Joan
Williams, Amy
Teresa Martinez, Maria
Ritzen, Hanna
Paris, Lorena
O'Connor, Miriam
De la Cruz Merino, Luis
Santaballa, Ana
Martinez-Janez, Noelia
Anton, Fernando Moreno
Fernandez, Isaura
Company, Jesus Alarcon
Guerra, Juan Antonio
Ruiz-Borrego, Manuel
Morris, Patrick G.
Portela, Marta
Herranz, Jesus
Caballero, Rosalia
Bergqvist, Mattias
Rojo Todo, Federico Gustavo
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2-breast cancer
Teran, Eduardo
Lozano, Rebeca
Rodriguez, Cesar A.
Abad, Mar
Figuero, Luis
Munoz, Jose Antonio
Cigarral, Belen
Rodrigues, Aline
Sancho, Magdalena
Gomez, M. Asuncion
Morchon, Daniel
Montero, Juan Carlos
Sayagues, Jose Maria
Ludena, M. Dolores
Fonseca, Emilio
CANCER MEDICINE, 2024, 13 (17):
[6] A systematic literature review of the prevalence of PIK3CA mutations and mutation hotspots in HR+/HER2-metastatic breast cancer
Mollon, Lea
Aguilar, Alejandra
Anderson, Elizabeth
Dean, Joni
Davis, Lisa
Warholak, Terri
Aizer, Ayal A.
Platt, Emma
Bardiya, Aditya
Tang, Derek
CANCER RESEARCH, 2018, 78 (13)
[7] Association between PIK3CA mutation status and development of brain metastases in HR+/HER2-metastatic breast cancer
Fitzgerald, D. M.
Muzikansky, A.
Pinto, C.
Henderson, L.
Walmsley, C.
Allen, R.
Ferraro, G. B.
Isakoff, S.
Moy, B.
Oh, K.
Shih, H. A.
Dias-Santagata, D.
Iafrate, A. J.
Bardia, A.
Brastianos, P. K.
Juric, D.
ANNALS OF ONCOLOGY, 2019, 30
[8] Testing patterns and prevalence of PIK3CA, AKT1, and PTEN alterations among patients (pts) with HR+/HER2-metastatic breast cancer (mBC) in the US
Park, Leah
Thompson, Samantha L.
Roose, James
Lu, Yichen
Chaki, Moumita
Lam, Clara
Iorgulescu, Bryan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[9] PIK3CA mutational status in tissue & plasma as a prognostic tool in HR+/HER2-breast cancer (BC)
Brage, Eduardo Teran
Mejorada, Rebeca Lozano
Francoso, Aline Rodrigues
Leon, Jose Antonio Munoz
Gutierrez, Alvaro Lopez
Figuero-Perez, Luis
Araujo, Daniel Morchon
Martinez, Maria Garijo
Ruiz, Jonnathan Roldan
Hernandez, Maria Mar Abad
de Salas, Magdalena Sancho
Sanchez, Emilio Fonseca
Sanchez, Cesar Augusto Rodriguez
CANCER RESEARCH, 2024, 84 (09)
[10] Prognostic value of PIK3CA mutational status in tissue & plasma in HR+/HER2-breast cancer (BC)
Lozano Mejorada, R.
Teran Brage, E.
Munoz Leon, J. A.
Lopez Gutierrez, A.
Figuero Perez, L.
Rodrigues Francoso, A.
Seijas Tamayo, R.
Morchon Araujo, D.
Garijo Martinez, M. D. C.
Roldan-Ruiz, J.
Abad Hernandez, M. M.
Sancho de Salas, M.
Fonseca Sanchez, E.
Rodriguez Sanchez, C. A.
ANNALS OF ONCOLOGY, 2023, 34 : S389 - S389

← 1 2 3 4 →